Our recently published NMA for L858R mutation revealed that gefitinib plus PbCT was the most efficacious in prolonging PFS, while the current NMA for 19del indicated that erlotinib plus bevacizumab or ramucirumab were the most optimal one and this further demonstrated the potential difference in tumor biology and sensitivity to EGFR-TKIs between these two mutant subgroups [44,48]. Here, EGFR is linked to neoplasm.